Bath Savings Trust Co grew its stake in Edwards Lifesciences Corp (NYSE:EW) by 3.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,658 shares of the medical research company’s stock after acquiring an additional 790 shares during the period. Bath Savings Trust Co’s holdings in Edwards Lifesciences were worth $3,298,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. IHT Wealth Management LLC grew its holdings in Edwards Lifesciences by 84.6% during the first quarter. IHT Wealth Management LLC now owns 932 shares of the medical research company’s stock valued at $126,000 after purchasing an additional 427 shares during the period. Gulf International Bank UK Ltd grew its holdings in Edwards Lifesciences by 0.7% during the first quarter. Gulf International Bank UK Ltd now owns 66,330 shares of the medical research company’s stock valued at $9,254,000 after purchasing an additional 450 shares during the period. Daiwa Securities Group Inc. grew its holdings in Edwards Lifesciences by 9.1% during the first quarter. Daiwa Securities Group Inc. now owns 6,891 shares of the medical research company’s stock valued at $961,000 after purchasing an additional 572 shares during the period. WealthPLAN Partners LLC grew its holdings in Edwards Lifesciences by 22.2% during the first quarter. WealthPLAN Partners LLC now owns 3,225 shares of the medical research company’s stock valued at $450,000 after purchasing an additional 585 shares during the period. Finally, Endurant Capital Management LP grew its holdings in Edwards Lifesciences by 5.2% during the fourth quarter. Endurant Capital Management LP now owns 12,216 shares of the medical research company’s stock valued at $1,377,000 after purchasing an additional 600 shares during the period. 80.90% of the stock is owned by institutional investors.
Edwards Lifesciences traded up $0.92, reaching $146.46, during trading on Thursday, according to Marketbeat. The company had a trading volume of 930,872 shares, compared to its average volume of 1,342,896. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.63 and a current ratio of 2.07. Edwards Lifesciences Corp has a 12 month low of $100.20 and a 12 month high of $155.22. The firm has a market cap of $30.68 billion, a P/E ratio of 38.37, a PEG ratio of 2.13 and a beta of 0.64.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, April 24th. The medical research company reported $1.22 EPS for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.11. The business had revenue of $938.00 million for the quarter, compared to analyst estimates of $936.69 million. Edwards Lifesciences had a net margin of 17.36% and a return on equity of 28.60%. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.94 earnings per share. sell-side analysts anticipate that Edwards Lifesciences Corp will post 4.63 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on EW. Sanford C. Bernstein began coverage on shares of Edwards Lifesciences in a report on Wednesday, June 27th. They set a “market perform” rating and a $165.00 price objective for the company. ValuEngine cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, June 6th. SunTrust Banks reaffirmed a “buy” rating and issued a $180.00 price target on shares of Edwards Lifesciences in a research note on Tuesday, April 10th. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences to $145.00 and gave the company an “outperform” rating in a research note on Wednesday, May 23rd. Finally, Zacks Investment Research lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $150.00.
In other news, VP Larry L. Wood sold 6,300 shares of the business’s stock in a transaction on Friday, June 15th. The shares were sold at an average price of $151.86, for a total value of $956,718.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Huimin Wang sold 3,800 shares of the business’s stock in a transaction on Friday, May 4th. The stock was sold at an average price of $131.93, for a total transaction of $501,334.00. Following the completion of the sale, the vice president now directly owns 85,016 shares in the company, valued at approximately $11,216,160.88. The disclosure for this sale can be found here. In the last three months, insiders sold 201,582 shares of company stock worth $27,531,518. 1.84% of the stock is currently owned by insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.